China
Africa
Explore chapters and articles related to this topic
Patient Portals Offer Opportunities for Patient-Provider Interaction at Children’s Hospital of Philadelphia
Published in Jan Oldenburg, Dave Chase, Kate T. Christensen, Brad Tritle, Engage!, 2020
Since the electronic health record (EHR) does not have functionality to analyze a patient’s status regarding complex legal criteria, CHOP faced the task of defining portal policies that would cover all of the laws’ provisions.
Assessment, classification and documentation of injury
Published in Jason Payne-James, Richard Jones, Simpson's Forensic Medicine, 2019
Jason Payne-James, Richard Jones
Chop injuries may be caused by a variety of implements that are generally heavy, and relatively blunt, bladed instruments. These include some machetes, Samurai swords and axes. Because of the variability of the ‘blade’, injuries sustained may be a mixture of sharp and blunt force wounds, typically involving bruised, crushed and abraded wound margins. These are often referred to as ‘chop’ wounds. Fractures and amputations may also result from the use of such implements and substantial scarring may ensue (Figure 8.26). It is with implements such as these that interpretation of the nature of wounds (sharp vs blunt, slash vs stab) may be particularly challenging.
Anaplastic thyroid carcinoma and thyroid lymphoma
Published in David S. Cooper, Jennifer A. Sipos, Medical Management of Thyroid Disease, 2018
Ashish V. Chintakuntlawar, Keith C. Bible
Historically, based upon recent reviews (63, 82) chemotherapy was administered to almost half of the patients with PTL. The most commonly used regimens were CHOP or R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). These regimens are well tolerated even in elderly patients with PTL and can be curative even in disseminated PTL (64). A review of the published literature suggested that the addition of chemotherapy to radiation therapy significantly lowered distant and overall recurrence (83). More recent studies indicate 5-year overall survival rates of 74–87% (63, 64, 77). Older age, advanced stage, aggressive histologic subtype, and lack of combined modality treatment were associated with worse survival (66).
Burden of illness and treatment patterns among patients with peripheral T-cell lymphoma in the US healthcare setting
Published in Current Medical Research and Opinion, 2021
Allison A. Petrilla, Anne Shah, Joseph Feliciano, Joseph Woolery, Thomas W. LeBlanc
Diagnosis and management of PTCL present a series of challenges for clinicians. First, the clinical presentation of PTCL is often complex and patients have high HRU. For example, approximately one in four patients had previously been diagnosed with other NHL or Hodgkin lymphoma before receiving a diagnosis of PTCL, potentially signifying initial misdiagnosis and resulting in a significant delay in initiating the proper treatment. Results of this study suggest no clear standard of care. While CHOP was the most commonly administered regimen, a large proportion of patients were treated with non-CHOP regimens. Very few patients in this study received SCT, which could be due to factors such as low clinician awareness of SCT as a potential treatment option, and perhaps the consideration of patient fitness for transplant due to concurrent comorbidities. A recent prospective study reported that even among patients with PTCL who achieved complete remission, only around 30% received a SCT; physician choice, PTCL subtype, and patient age/comorbidities were the major factors cited by treating physicians for not considering transplantation33.
Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm
Published in Expert Review of Anticancer Therapy, 2020
Sophia S. Lee, Deborah McCue, Naveen Pemmaraju
With no standardized therapeutic approach, treatment response in BPDCN has been dismal. Skin directed therapies have been suggested for isolated lesions, but this method did not provide long term benefit [6]. Most have been treated with various systemic chemotherapy, and one of the largest retrospective studies involving >30 patients reported a complete remission (CR) rate of 41 to 55% [1]. Historically, a CHOP-like treatment regimen, commonly used for non-Hodgkin lymphoma, was used. However, this regimen was shown to produce less responses compared to either ALL-like or acute myeloid leukemia (AML)-like regimens [14]. Between the two leukemia-like regimens, ALL-type therapies appear more effective in numerous studies. Some who have failed ALL-type therapies have been shown to harbor mutations commonly seen in AML and MDS; this subpopulation appeared to have better responses to AML-like regimens in some studies [6,24]. High dose methotrexate with asparaginase (Aspa-MTX) chemotherapy also achieved a high response rate with low toxicity profile, providing another regimen to be considered prior to HSCT, particularly in the absence of availability of CD123-directed therapy [14,25]. Likewise, the use of lenalidomide, bortezomib, and dexamethasone regimen have yielded complete responses in two and clinical remission in one patient [26].
Adverse effects of chemotherapy and their management in Pediatric patients with Non-Hodgkin’s Lymphoma in Kenya: A descriptive, situation analysis study
Published in Expert Review of Anticancer Therapy, 2019
Linda Opanga, Mercy N. Mulaku, Sylvia A. Opanga, Brian Godman, Amanj Kurdi
Despite their benefits, the various chemotherapy combinations, including CHOP, have acute and chronic side-effects. The most common side-effects include alopecia, nausea and vomiting, bone marrow suppression and a general reduction in patient’s quality of life. Some of these side effects are dose-dependent and vary from one child to another, whilst others are common among all pediatric patients. The presence and severity of side effects also depend on patients’ ages, weight, body surface area, and type of chemotherapy. Consequently, there is often a need for dose adjustments during prescribing [20,21]. We are also aware that chemotherapy causes a reduction in white blood cell count, especially neutrophils, which makes patients susceptible to secondary infections during their nadir period [22]. This needs to be carefully monitored. Pain can also occur as a consequence of tissue destruction and invasion by cancerous cells, and it may also be a side effect of chemotherapy. Typically, pain is managed using analgesics in line with the WHO pain ladder [23].